絞り込み

17057

広告

Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials.

著者 Hauschild A , Ascierto PA , Schadendorf D , Grob JJ , Ribas A , Kiecker F , Dutriaux C , Demidov LV , Lebbé C , Rutkowski P , Blank CU , Gutzmer R , Millward M , Kefford R , Haas T , D'Amelio A , Gasal E , Mookerjee B , Chapman PB
Eur J Cancer.2019 Dec 18 ; 125():114-120.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9view , 0users)

Full Text Sources

Medical

Research Materials

Previous analyses of BREAK-2 and BREAK-3 showed that durable outcomes lasting ≥3 years are achievable with dabrafenib in some patients with BRAF V600-mutant metastatic melanoma (MM); however, additional follow-up is needed to fully characterise the long-term impact of dabrafenib in these patients.
PMID: 31864178 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード